{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:22:39Z","timestamp":1790907759429,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T00:00:00Z","timestamp":1234396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00228-009-0621-z","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T11:31:12Z","timestamp":1234351872000},"page":"545-549","source":"Crossref","is-referenced-by-count":62,"title":["Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders"],"prefix":"10.1007","volume":"65","author":[{"given":"N.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,12]]},"reference":[{"key":"621_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"621_CR2","first-page":"255","volume":"19","author":"L Kumar","year":"2006","unstructured":"Kumar L (2006) Chronic myelogenous leukemia (CML): an update. Nat Med J India 19:255\u2013263","journal-title":"Nat Med J India"},{"key":"621_CR3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMe030009","volume":"348","author":"K Peggs","year":"2003","unstructured":"Peggs K, Mackinnon S (2003) Imatinib mesylate\u2014the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048\u20131050","journal-title":"N Engl J Med"},{"key":"621_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Kaeda J (2003) Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias. Lancet Oncol 4:75\u201385","journal-title":"Lancet Oncol"},{"key":"621_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E (1996) Effects of a selective inhibitors of the Abl tyrosinekinase on the growth of BCR\u2013ABL positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"621_CR6","unstructured":"Cancer Care Ontario (2008) Revised Drug formulary. Available via DIALOG: http:\/\/www.cancercare.on.ca\/pdfdrugs\/Imatinib\u2014Mesylate.pdf Accessed 12 Aug 2008"},{"key":"621_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P Coutre le","year":"2004","unstructured":"le Coutre P, O\u2019Dwyer ME, Druker BJ (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313\u2013323","journal-title":"Cancer Chemother Pharmacol"},{"key":"621_CR8","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"621_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","volume":"804","author":"T Velpandian","year":"2004","unstructured":"Velpandian T, Kumar L, Arora B (2004) Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinb in biological samples. J Chromatogr B 804:431\u2013434","journal-title":"J Chromatogr B"},{"key":"621_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"621_CR11","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses for standard dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"621_CR12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S (2003) Detection of BCR\u2013ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood 102:276\u2013283","journal-title":"Blood"},{"key":"621_CR13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D (2006) Frequency and clinical significance of BCR\u2013ABL mutations in patients with chronic myeloid leukaemia treated with imatinib mesylate. Leukemia 20:1767\u20131773","journal-title":"Leukemia"},{"key":"621_CR14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","volume":"24","author":"GR Wilkinson","year":"1996","unstructured":"Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475\u2013490","journal-title":"J Pharmacokinet Biopharm"},{"key":"621_CR15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","volume":"26","author":"L Wojnowski","year":"2004","unstructured":"Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192\u2013199","journal-title":"Ther Drug Monit"},{"key":"621_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukaemia cells to treatment with imatinib mesylate. Leukemia 18:401\u2013408","journal-title":"Leukemia"},{"key":"621_CR17","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739\u20133745","journal-title":"Blood"},{"key":"621_CR18","first-page":"841","volume":"85","author":"Y Wei","year":"2006","unstructured":"Wei Y, Hardling M, Olsson B (2006) Not all imatinib resistance in CML are BCR\u2013ABL kinase domain mutations. J Clin Pharm 85:841\u2013847","journal-title":"J Clin Pharm"},{"key":"621_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-006-0105-3","volume":"62","author":"N Rais","year":"2006","unstructured":"Rais N, Chawla YK, Kohli KK (2006) CYP3A phenotypes and genotypes in north indians. Eur J Clin Pharm 62:417\u2013422","journal-title":"Eur J Clin Pharm"},{"key":"621_CR20","first-page":"9","volume":"54","author":"V Lamba","year":"1988","unstructured":"Lamba V, Lamba JK, Dilawari JB (1988) Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharm 54:9\u201311","journal-title":"Eur J Clin Pharm"},{"key":"621_CR21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"LC Crossman","year":"2005","unstructured":"Crossman LC, Druker BJ, Deininger MWN (2005) HOCT1 and resistance to imatinib. Blood 106:1133\u20131134","journal-title":"Blood"},{"key":"621_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2008","unstructured":"Kantarjian HM, Talpaz M, OBrien S (2008) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with CML. Blood 101:473\u2013475","journal-title":"Blood"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0621-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0621-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0621-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:57Z","timestamp":1558702317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0621-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0621-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,12]]}}}